KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Current Deferred Revenue (2016 - 2025)

Alnylam Pharmaceuticals' Current Deferred Revenue history spans 17 years, with the latest figure at $4.8 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 91.27% year-over-year to $4.8 million; the TTM value through Dec 2025 reached $4.8 million, down 91.27%, while the annual FY2025 figure was $4.8 million, 91.27% down from the prior year.
  • Current Deferred Revenue reached $4.8 million in Q4 2025 per ALNY's latest filing, up from $2.5 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $149.5 million in Q4 2021 to a low of $2.5 million in Q3 2025.
  • Average Current Deferred Revenue over 5 years is $71.4 million, with a median of $73.7 million recorded in 2021.
  • Peak YoY movement for Current Deferred Revenue: surged 144.04% in 2023, then plummeted 96.42% in 2025.
  • A 5-year view of Current Deferred Revenue shows it stood at $149.5 million in 2021, then plummeted by 71.83% to $42.1 million in 2022, then soared by 144.04% to $102.8 million in 2023, then plummeted by 46.01% to $55.5 million in 2024, then plummeted by 91.27% to $4.8 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Current Deferred Revenue are $4.8 million (Q4 2025), $2.5 million (Q3 2025), and $15.1 million (Q2 2025).